Sign In
Buy IRON
$70.35
+2.35 (+3.46%)
At Close: Jun 03, 2026
WATERTOWN, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
WATERTOWN, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine, Inc. (IRON) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
04:39pm, Wednesday, 10'th Sep 2025
Disc Medicine, Inc. (NASDAQ:IRON ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT Company Participants John Quisel - CEO, President & Director Conference Call P
Disc Medicine (IRON) Q2 Loss Widens 109%
12:24pm, Thursday, 07'th Aug 2025
Disc Medicine (IRON -1.79%), a clinical-stage biopharmaceutical company advancing treatments for hematologic diseases, released its second quarter 2025 earnings on August 7, 2025. Reflecting investmen
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
08:30am, Monday, 14'th Jul 2025
WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress
07:30am, Thursday, 12'th Jun 2025
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine to Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 28'th May 2025
WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress
09:30am, Wednesday, 14'th May 2025
WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
08:00am, Wednesday, 07'th May 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t
Disc Medicine: Forging Ahead In Hematology
07:13am, Wednesday, 09'th Apr 2025
Disc Medicine's strong financial position, with $489.9 million in cash and securities, ensures funding through 2028, reducing near-term financing risks. Lead asset Bitopertin shows promise in treating
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy
01:05pm, Friday, 14'th Mar 2025
Disc Medicine, Inc. (IRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know
11:00am, Monday, 03'rd Mar 2025
The consensus price target hints at a 68.8% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
08:00am, Thursday, 27'th Feb 2025
WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 26'th Feb 2025
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
WILLIAMS SONOMA LAUNCHES NEW COLLABORATION WITH IRON CHEF MASAHARU MORIMOTO
09:00am, Wednesday, 19'th Feb 2025
SAN FRANCISCO--(BUSINESS WIRE)-- #Fortune500--Chef Morimoto Launches New Exclusive Food Collaboration with Williams Sonoma.
